Importer of Controlled Substances; Notice of Application, 23949 [E6-6114]
Download as PDF
<![CDATA[
23949
Federal Register / Vol. 71, No. 79 / Tuesday, April 25, 2006 / Notices
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
wwhite on PROD1PC65 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
September 16, 2005, Hospira, Inc., 1776
North Centennial Drive, McPherson,
Kansas 67460–1247, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Remifentanial (9739), a
basic class of controlled substance listed
in Schedule II.
The company plans to import the
basic class of controlled substance for
use in dosage unit manufacturing.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 25, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
VerDate Aug<31>2005
16:59 Apr 24, 2006
Jkt 208001
Dated: April 18, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–6114 Filed 4–24–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
§ 1301.34(a), this is notice that on
November 15, 2005, Johnson Matthey
Inc., Pharmaceutical Materials, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in Schedule II:
Drug
Schedule
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
II
The company plans to import the
listed controlled substances as raw
materials for use in the manufacture of
bulk controlled substances for
distribution to its customers.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 25, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: April 18, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–6113 Filed 4–24–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
November 2, 2005, Noramco Inc., 500
Old Swedes Landing Road, Wilmington,
Delaware 19801, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in Schedule
II:
Drug
Raw Opium (9600) .......................
E:\FR\FM\25APN1.SGM
25APN1
Schedule
II
]]>Agencies
[Federal Register Volume 71, Number 79 (Tuesday, April 25, 2006)]
[Notices]
[Page 23949]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-6114]
[[Page 23949]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on September 16, 2005, Hospira, Inc., 1776 North Centennial Drive,
McPherson, Kansas 67460-1247, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as an importer of
Remifentanial (9739), a basic class of controlled substance listed in
Schedule II.
The company plans to import the basic class of controlled substance
for use in dosage unit manufacturing.
Any manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances may
file comments or objections to the issuance of the proposed
registration and may, at the same time, file a written request for a
hearing on such application pursuant to 21 CFR 1301.43 and in such form
as prescribed by 21 CFR 1316.47.
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than May 25, 2006.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substance listed
in Schedule I or II are, and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: April 18, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-6114 Filed 4-24-06; 8:45 am]
BILLING CODE 4410-09-P
